Text Size
Santen Global

2008 IR News

RSS

IR News

Santen Announces Financial Result for the Second Quarter ended September 30, 2008
Santen Announces Approval of TAPROS™ for Glaucoma and Ocular Hypertension Treatment in Japan
Revision of Performance Forecast
Santen Announces Financial Result for the First Quarter ended June 30, 2008
Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)
Notice on the Allotment of Stock Options (Stock Acquisition Rights)
Santen Files Manufacturing and Marketing Approval for Corneal and Conjunctival Epithelial Disorder Treatment
Santen and MacuSight Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions
Santen to Issue Stock Acquisition Rights to the Directors for the Purpose of Granting Stock Options
Santen to Issue Stock Acquisition Rights to the Corporate Officers for the Purpose of Granting Stock Options
Extension of Nara Research and Development Center
Notice on Board of Directors, Corporate Auditors and Corporate Officers
Santen Oy Receives Marketing Authorization for its Glaucoma and Ocular Hypertension Treatment, TAFLOTAN® in Denmark
Notice Regarding the Completion of Purchase of the Company's Own Shares in the Market
Notice Regarding the Purchase of the Company's Own Shares in the Market
Santen to Lift Condition for Approval of PAPILOCK Mini Ophthalmic Solution 0.1%
Santen to Purchase Own Shares
Santen Announces Financial Result for the Third Quarter ended December 31, 2007 Appendix
Santen to Launch Nutritional Supplement Sante Lutax
News Archive
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved